Showing 381 - 400 results of 45,525 for search '(( 50 ((a decrease) OR (nn decrease)) ) OR ( 5 ((nm decrease) OR (mean decrease)) ))', query time: 1.28s Refine Results
  1. 381

    Calcineurin acts as a Ca<sup>2+</sup> sensor for metamodulation of LP I<sub>h</sub> in 5nM DA. by Wulf-Dieter C. Krenz (693267)

    Published 2015
    “…Black asterisks indicate that a one-way ANOVA on the four DA-treatment groups with Tukey’s post hoc tests that made all pair wise comparisons showed that the decrease observed for the TTX + DA + (+50 OSC) treatment group was significantly different from the other three DA treatment groups, and that those three DA treatment groups [(TTX+DA, TTX+DA+FK506, TTX+DA+FK506+(+50 OSC)] were not significantly different from one another: (F (3,26) = 11.08; p = 0.0001). …”
  2. 382

    Decreased capillary density and cardiac fibrosis in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> heart. by Craig Bolte (299486)

    Published 2013
    “…Capillary density was decreased in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> hearts at P11 (A–B, I), while coronary vessel formation was not altered (C–D). …”
  3. 383
  4. 384
  5. 385
  6. 386

    CNP decrease mitochondrial membrane potential and induce mitochondrial fragmentation in melanoma cells. by Elif Aplak (7430123)

    Published 2020
    “…<p>A, 300 μM CNP (4 h) significantly decreased mitochondrial membrane potential in A375 cells, but not in melanocytes, indicated by changes of TMRM dependent fluorescence in mitochondria. …”
  7. 387

    SPL treatment decreases diabetes-induced decrement in protein expression of cldn-5 in glomeruli (GL) and cldn-2 and occldn in proximal tubules (PT). by Eduardo Molina-Jijón (4020464)

    Published 2017
    “…<p>SPL prevents diabetes-induced decrease of cldn-5 protein expression (A and B) in GL, and mRNA (F) and protein expression of cldn-2 (A and C), and protein expression of occldn (A and D) in PT (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177362#pone.0177362.s002" target="_blank">S2 Fig</a>). …”
  8. 388
  9. 389
  10. 390
  11. 391
  12. 392

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  13. 393
  14. 394
  15. 395
  16. 396
  17. 397
  18. 398
  19. 399
  20. 400